MedTrace Logo

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

NCT05548348 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-09-21

No results posted yet for this study

Summary

Furmonertinib, a newly-designed pan-EGFR-TKI with a trifluoroethoxypyridine-based molecule structure, has shown promising clinical efficacy in EGFR Ex19del/L858R/T790M/Ex20ins mutant advanced NSCLC with an acceptable safety profile without new signals from 80mg to 240mg dose level in phase 1-3 clinical trials. Whether EGFR G719X/S768I/L861Q mutation positive advanced NSCLC patients can benefit from first-line furmonertinib 160mg per day has not been reported. This study aims to investigate the efficacy and safety of furmonertinib 160mg per day in EGFR G719X/S768I/L861Q mutant patients under first-line treatment of advanced NSCLC setting.

Conditions

Interventions

DRUG

Furmonertinib 160 mg, Q.D.

Furmonertinib will be administered orally at a dose of 160 mg per time, Q.D.

Sponsors & Collaborators

  • Army Specialty Medical Center

    collaborator UNKNOWN

  • The Second Affilicated Hospital of Chongqing Medical University

    collaborator UNKNOWN

  • Chongqing University Cancer Hospital

    lead OTHER

Principal Investigators

  • Yongsheng Li, M.D. & Ph.D. · Chongqing University Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-26
Primary Completion
2023-12-31
Completion
2025-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05548348 on ClinicalTrials.gov